Claire Mazumdar, CEO of Bicara Therapeutics Inc. (BCAX +1.28%), recently sold 8,234 shares of common stock for approximately $154,000, as reported in an SEC Form 4 filing. The transactions occurred between March 4 and March 6, 2026, at a weighted average price of $18.74 per share. Notably, this sale represents less than 2.5% of her total direct stake of 339,392 shares, indicating it was primarily a liquidity event rather than a reduction in her long-term holdings.
This sale is part of a 10b5-1 trading plan initiated in February 2025 and involved shares originating from an option exercise. Despite the sale, Mazumdar retains significant equity in the company, which is crucial as Bicara’s lead product, ficerafusp alfa, has received FDA breakthrough therapy designation and is approaching pivotal trial milestones. The upcoming Q4 and full-year 2025 results, scheduled for March 30, will provide further insights into the company’s trajectory.
For investors, Mazumdar’s continued substantial holdings and the promising clinical developments surrounding ficerafusp alfa represent key factors to watch. The interim analysis expected in mid-2027 could serve as a critical catalyst for the stock, making the company’s upcoming earnings report particularly significant.
Source: fool.com